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Edited by Beat ImhofAbstract To identify chicken IL-2R a chain (chCD25), the
cDNA of chCD25 was cloned and mapped onto chicken chromo-
some 1. The polyclonal and monoclonal antibodies raised from
the recombinant chCD25 speciﬁcally bound to the cell surface
of splenic mononuclear cells (SMC) and inhibited chicken IL-
2-dependent proliferation of T cells. Flow cytometry analysis re-
vealed that chCD25 molecules could be expressed on the surface
of monocytes/macrophages, thrombocytes, CD4+ and CD8+
cells as well as tissue cells. Importantly, the CD4+CD25+ and
CD8+CD25+ cells were upregulated dramatically in chickens in-
fected with H9N2 avian inﬂuenza virus. These results conﬁrm
that the cloned cDNA is the nucleotide sequence of chicken
IL-2R, and suggest that chicken CD4+CD25+ and CD8+CD25+
cells may play an important role in immune responses induced by
H9N2 virus, and the monoclonal antibodies to chCD25 may be
useful for investigating biological functions of chicken regulatory
T cells.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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IL-2 is a lymphokine synthesized and secreted mainly by
activated T lymphocytes and plays a pivotal role in the growth
and diﬀerentiation of T and B lymphocytes, monocytes and
natural killer cells [1]. The human IL-2 receptor (IL-2R) is a
heterotrimeric complex consisting of a (CD25), b (CD122)
and c (CD132) chains [2–4]. The CD25 chain is a transmem-
brane glycoprotein containing N- and O-linked glycosyl units
with an apparent molecular weight of 55 kDa [5], and is spe-
ciﬁc for IL-2 and increases receptor aﬃnity resulting in a dras-
tic enhancement of T lymphocyte proliferation [6]. Recent data
from crystal analysis suggest that the binding of CD25 to IL-2Abbreviations: CFA, complete Freund’s adjuvant; chCD25, chicken
IL-2R a chain; chCD4+CD25+, chicken CD4+CD25+ cell;
chCD8+ CD25+, chicken CD8+CD25+ cell; FCM, ﬂow cytometry;
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chain, and CD25 has been used to distinguish a functionally
relevant suppressive T-cell subpopulation [7–11].
CD25 expression has been investigated widely in vitro and
in vivo [5,12,13]. Currently, two main populations of
CD4+CD25+ cells have been hypothesized naturally occurring
regulatory T cells (Treg) that mature in the thymus and induced
Treg cells that acquire their activity during activation in vitro or
in vivo [14–16]. CD4+CD25+ cells are one group of suppressor T
cells identiﬁed as the best-characterized regulatory T cells
[16,17]. CD4+CD25+ cells can suppress host immune responses
and modulate immune responses in the setting of autoimmune
diseases, allergy, transplantation and anti-tumor immunity
[18,19]. Recent studies have also suggested that Treg cells have
a potential role in suppressing virus-speciﬁc CD8+T-cell eﬀector
functions during acute and chronic viral infections, such as the
hepatitis C virus, human immunodeﬁciency virus, and cytomeg-
alovirus [20–23]. Simultaneously, a population of CD8+CD25+
cells was revealed in the human thymus and MHC class II-deﬁ-
cient mice, whose functions are similar to CD4+CD25+ human
regulatory thymocytes [24]. In addition, CD8+CD25+ T cells
have been suggested as potent memory cells in old age [25].
Since Sundick et al. identiﬁed the chicken cDNA sequence for
IL-2 (chIL-2), it has been studied as a vaccine adjuvant due to its
pivotal role in activating T cell proliferation [26–29]. However,
it is unclear whether chIL-2 exerts biological function by bind-
ing its cell receptor. Some researchers had reported a monoclo-
nal antibody (mAb) recognizing the activated chicken T
lymphocytes [30–32]. In this study, a cell receptor binding to
chIL-2, named chicken CD25 (chCD25) according to human
IL-2R a chain (CD25), was expressed in prokaryotic and
eukaryotic cells. The monoclonal antibodies to chCD25 were
produced and the immunophenotypes of chCD25+ cells were
analyzed in vitro and in vivo. To the best of our knowledge, this
is the ﬁrst report of the functional analysis of chCD25 protein.2. Materials and methods
2.1. Virus and cells
Vero cells were maintained in minimum essential medium (MEM)
(Gibco BRL, Gaithersburg, MD), supplemented with 10% newborn
calf serum (NCS). The A/Ck/JD/323/2001 avian inﬂuenza virus
(H9N2) (107.5 EID50/0.1 ml) was stored in our laboratory. Splenic
mononuclear cells (SMC) were prepared as described previously [33].
Brieﬂy, SPF Leghorn chickens at 30 days old (purchased from Beijing
Merial Vital Laboratory Animal Technology Co. Ltd., Beijing, China)
were sacriﬁced by intravenous barbiturates. Spleens were collected
aseptically and rinsed with Ca2+- and Mg2+-free PBS (717 mmol/Lblished by Elsevier B.V. All rights reserved.
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sors, and then passed through a stainless steel screen to obtain a homo-
geneous cell suspension. The splenic cell suspension was then overlaid
on an equal volume of Histopaque-1077 (Sigma Chemical Co., St.
Louis, MO). An interface rich in SMC was recovered after centrifuga-
tion at 500 · g for 30 min at 4 C. Finally, the SMC were suspended
with RPMI 1640 medium supplemented with 10% NCS.
2.2. RNA isolation, RT-PCR and DNA sequencing
The SMC were cultured by 6-well ﬂat-bottom plates in RPMI 1640
medium supplemented with 10% NCS at a ﬁnal concentrations of
5 · 106 cells/ml containing 10 lg/ml concanavalin A (con A), and incu-
bated at 37 C for 21 h. The con A-stimulated SMC were collected by
the centrifugation at 500 · g for 5 min at 4 C. Total cellular RNA
was extracted with Trizol reagent (Invitrogen, Carlsbad, CA), from
which the cDNAs were synthesized from total cellular RNA using an
Oligo (dT)18 primer. The nucleic acid sequence of chCD25 was then
ampliﬁed using PCR with a pair of primers (upstream primer
5 0-ACCATTTGCTGACCACA GAG-3 0 and downstream primer
5 0-ATTATGCACACTTTTTTG-3 0) designed by cIL-2Ra cDNA
sequence (GenBank accession No. AF143806). The PCR assay was car-
ried out with conditions consisting of 30 cycles of denaturation at 95 C
for 2 min, primer annealing at 52 C for 45 s and DNA extension at
72 C for 1 min. Lastly, the ﬁnal extension was carried out at 72 C
for 10 min. The ampliﬁed products were puriﬁed, sequenced, and in-
serted into pMD18-T vector. The nucleotide sequence of open reading
frame (ORF) for chCD25, along with those of the mammalian IL-
2Ra cDNA sequences deposited in the GenBank library, were analyzed
by DNASTAR 5.0 software (DNASTAR Inc., Madison, WI). A signal
peptide of putative chCD25 protein was predicted by SignalP version
2.0 (SignalP-NN and SignalP-HMM software) of SignalP World Wide
Web server [34]. The extracellular domain of chCD25 protein without
the signal peptide was deduced by DAS software (www.sbc.su.se/~mik-
los/DAS/). Eventually, the locus of chCD25 gene was assigned on chro-
mosome according to the published chicken genome sequence (http://
www.genome.ucsc.edu/).
2.3. Bacterial expression of recombinant chCD25 fusion protein
The nucleotide sequence encoding chCD25 extracellular domain was
ampliﬁed by PCR from the complete chCD25 nucleotide sequence
using the following primers: forward primer 5 0-ATGAATTCGAT-
AAATGCCCACGT-CTTTTC-3 0 containing an EcoRI site and
reverse primer 5 0-CGGTCGACTC-AGGATAGCTGCTTGTTTA-
TAG-3 0 containing a SalI site. The PCR product was digested with
EcoRI and SalI, and directly inserted into the corresponding sites of
the pET32a expression vector (Novagen, Madison, WI). The resulting
plasmid was designated as pET32a-chCD25. The recombinant
chCD25 protein (rchCD25) was expressed as a fusion protein carrying
thioredoxin (Trx) and His tags after the pET32a-chCD25 were trans-
formed into E. coli BL21 (DE3) strain, and were puriﬁed by a nickel
column under denaturing conditions following manufacturer’s instruc-
tions (Qiagen Inc., Valencia, CA). The rchCD25 protein was analyzed
by SDS–polyacrylamide gel electrophoresis (SDS–PAGE) and
Western blot with the anti-His mAb (Amersham, USA) as described
previously [33].2.4. Raising antibodies to chCD25
Two white New Zealand female rabbits (12 weeks old) were injected
at multiple subcutaneous sites with 1 mg rchCD25 protein plus com-
plete Freund’s adjuvant (CFA, Sigma). The immunizations were
boosted two times at 14-day intervals with 0.6 mg rchCD25 fusion pro-
tein plus incomplete Freund’s adjuvant (IFA, Sigma).
Five SPF BALB/c mice were immunized subcutaneously with 50 lg
of rchCD25 protein in CFA, and boosted three times with an equiva-
lent dose in IFA. Two weeks later, the mice were injected intraperito-
neally with a dose of 100 lg rchCD25. Spleen lymphocytes were fused
with SP2/0 myeloma cells using standard procedures. The hybridoma
secreting antibodies against chCD25 was screened and cloned by a lim-
iting dilution technique. Further selection and conﬁrmation of mAbs
to chCD25 protein were conﬁrmed by the indirect ELISA as described
earlier [35], using Trx, cell lysates of E. coli BL21 (DE3) and rchCD25
as antigens. The subtype analysis of each mAb was performed using
SBA Clonotyping System/HRP (Southern Biotechnology Associates
Inc., Birmingham, AL).2.5. Eukaryotic expression of chIL-2Ra protein in Vero cells
To conﬁrm that anti-chCD25 pAb and mAbs were able to react with
the natural chCD25 protein, their reactivity was tested on Vero cells
expressing chCD25 protein. ORF for chCD25 was ampliﬁed using
PCR from the recombinant plasmid pMD18-T containing the cDNA
sequence of chCD25, and subcloned into the pEGFP-C2 plasmid
(BD Biosciences Clontech, Palo Alto, CA). The EGFP-tagged chCD25
plasmid DNA was introduced into Vero cells by Lipofectamine 2000
reagent (Invitrogen). The transfected cells began to be examined under
an inverted ﬂuorescence microscope at 3 h post-transfection. After
incubation for 19 h at 37 C, the cells were washed with PBST (con-
taining 0.05% Tween 20) and ﬁxed in methanol-acetone mixture (1:1,
V/V). Cells were then incubated with pAb and mAb to chCD25 fol-
lowed by HRP-labeled goat anti-rabbit/rat-IgG (Kirkegaard & Perry
Laboratories Inc., Gaithersburg, MD). Color development was carried
out with 3-amino-9-ethylcarbazole (BD Pharmingen, San Diego, CA).
2.6. Inhibition of chIL-2-stimulated T-cell proliferation
The anti-chCD25 mAbs and pAb were puriﬁed by fast protein liquid
chromatography (Amersham-Pharmacia Biotech, Piscataway, NJ),
and their protein concentrations were determined using a protein assay
kit based on the Bradford reagent (Biorad, Hercules, CA). The SMC
stimulated with con A for 48 h were incubated in RPMI 1640 medium
containing 0.1 mol/L a-methyl-mannoside for 30 min. Dead cells were
removed using Histopaque-1077 after centrifugation. Serial twofold
dilutions of pAb and mAbs to chCD25 protein (10 lg/ml) were mixed
with equal volume of live con A-stimulated SMC (5 · 106 cells/ml).
After 200 ll of mixture was seeded into 96-well plates and incubated
at 37 C for 2 h, 50 ll (12.5 lg/ml) of rchIL-2 protein [29] was added
to each well. After further incubation at 37 C for 48 h, 25 ll MTT
(5 mg/ml, Sigma) was added and reacted for 4 h before 100 ll of lysis
buﬀer (10% SDS, 0.01 mol/L HCl) was added. Plates were incubated
for 20 h at 37 C and optical density (OD) values were measured at
570 nm (630 nm as a reference wavelength). The SMC with only
chIL-2 or RPMI 1640 medium, were used as positive and negative con-
trols, respectively. The inhibition of cell proliferation was calculated
using the following formula as previously described [36]: inhibition =
(ODpositive control  ODsample)/(ODpositive control  ODnegative control) ·
100%.
2.7. Expression analysis of chCD25 protein in chicken tissues
The single cell suspensions were produced respectively from the car-
diac muscle, thymus, shankbone antrum, duodenum, brain, spinal
cord, spleen, kidneys, lungs, caecal tonsils and bursa of Fabricius from
three chickens. These cell suspensions were washed ﬁve times with PBS
and centrifuged at 500 · g. The thrombocytes were then isolated from
chicken blood using diﬀerential centrifugation as stated previously [37].
The monocytes/macrophages were further enriched from the SMC
adhering on the glass plate (adherent SMC) as described previously
[38]. Finally, SMC and adherent SMC were incubated in RPMI 1640
medium supplemented with 10% NCS at a ﬁnal concentration of
5 · 106 cells/ml and 10 lg/ml con A for 48 h in vitro.
Cells were suspended with PBS at a concentration of 1 · 107 cells/ml.
The chCD25 molecules, expressed in monocytes/macrophages, cdT
cells, thrombocytes, CD4+ and CD8+ cells as well as tissue cells, were
detected using ﬂow cytometry (FCM) assay as stated below.2.8. In vivo CD25 expression of chickens infected with H9N2 avian
inﬂuenza virus
To determine in vivo kinetics of chCD25 expression, fourteen 30-
day-old SPF Leghorn chickens were housed in negative-pressure isola-
tor cages with HEPA-ﬁltered air, and inoculated intra-nasally (i.n.)
with 107.5 EID50/0.1 ml H9N2 virus in a 0.5-ml volume. After being in-
fected with H9N2 virus for 24 h, SMC were collected from the infected
chickens using the above-mentioned method at 1-day intervals until
the 7th day post-infection. Fourteen uninfected SPF Leghorn chickens
were used as negative control. FCM analysis was carried out as men-
tioned below.2.9. Flow cytometry analysis
Tissue cells, SMC, adherent SMC and thrombocytes were incubated
with mAb to chCD25 and a secondary FITC/PE-labeled goat anti-
mouse-IgG (SBA) on ice, respectively. Except for tissue cells, the
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mouse anti-chicken CD4 (chCD4) or CD8 (chCD8) or cd T cell or
monocyte/macrophage mAbs (SBA), or FITC-conjugated mouse
anti-chicken chCD41/CD61(thrombocyte) mAb (Serotec Ltd, Oxford,
UK). Cells were analyzed using a Coulter XL ﬂow cytometer (Beck-
man, Fullerton, CA) with System II software. Cells incubated with
normal mouse serum and PE/FITC-conjugated mouse IgG1 (SBA)
were used as parallel controls.3. Results
3.1. Sequence, structure and chromosomal assignment of
chCD25 cDNA
The sequencing results showed that the chCD25 cDNA se-
quence (GenBank Accession No. AY772091) was 1027 bp in
length. An ORF consisting of 636 nucleotides was revealed
to encode a predicted precursor polypeptide of 211 amino 
 
 
 
 
 
 
 
 
A 
. . . . . . . . . 250 . . . . . . . . .
W Q R R Q R K S R R T I
W Q H R W R K S R R T I
. . . . . . . . . 2 10 . . . . . . . . .
- I N K Q L S H L M E A V I F - - - F
Q I Q T E M A A T M E T S I F T T E Y
P Q P T E T T A M T E T F V L T M E Y
. . . . . . . . . 90 . . . . . . . . .
Q Q P A R Q T Q S P A P P K - - - Q A
K E R - K T T E M Q S P M Q P V D Q A
K E Q Q T T T D M Q K P T Q S M H Q E
. . . . . . . . . 170 . . . . . . . . .
D R P C T N D - - - - - - - - - - - -
Q L I C T G E M E T S Q F P G E E K P
Q L T C V D E R E H H R F L A S E E S
. . . . . . . . . 130 . . . . . . . . .
I Y S V G Q V L H F K C P T G Y N K Q
H F V V G Q M V Y Y Q C V Q G Y R A L
H F V E G Q S V H Y E C I P G Y K A L
. . . . . . . . . 50 . . . . . . . . .
T L T I R C Q N V S G T A S W V H D E
S L Y M L C T G N S S H S S W D N Q C
L V Y M R C L G N - - - - S W S S N C
1 . . . . . . . . 10 . . . . . . . . .
D K C P - R L S T T E F A D V A A E T
E L C D D D P P E I P H A T F K A M A
E L C L Y D P P E V P N A T F K A L S
Chicken 
Human 
Mouse 
Chicken 
Human 
Mouse 
Chicken 
Human 
Mouse 
Chicken 
Human 
Mouse 
Chicken 
Human 
Mouse 
Chicken 
Human 
Mouse 
Chicken 
Human 
Mouse 
Human IL-2Rα  
64 bp 192 bp 111 bp 216 bp 
Chicken IL-2Rα  
186 bp 111 bp 234 bp 60bp 
Mouse IL-2Rα
 64 bp  177 bp 114 bp 
Untranslated region Tran
Fig. 1. Sequence analysis and comparison of the chCD25. (A) Alignment o
mouse. The conserved aa residues in all three mature CD25 proteins are m
shadow. (B) Comparison of gene structure of chCD25, CD25 and mCD25. W
represents an untranslated region.acids (aa) residues. Further signal peptide analysis revealed
that the chCD25 precursor polypeptide comprised of a signal
peptide with 20 aa residues at the N-terminus which was sim-
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truncating the signal peptide, the approximate molecular
weight of the mature chCD25 protein was 23.551 kDa. More-
over, the results of bioinformatics analysis showed that the
predicted mature chCD25 protein was composed of an extra-
cellular domain (172 aa), a membrane-spanning region (15
aa) and a cytoplasmic domain (4 aa).
In alignment analysis, when compared with human IL-2Ra
(CD25) and mouse IL-2Ra (mCD25) chains, the identities
for nucleic and amino acid sequences were 24.2%, and 15.6%
between chCD25 and CD25, and 28.9% and 19.3% between
chCD25 and mCD25. Data shown in Fig. 1A indicated that
there were seven conserved half-cystine residues between
mature chCD25 and CD25 as well as mCD25. Based on the260
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signed to chicken chromosome 1. In addition, the chCD25
cDNA was comprised of ﬁve exons and four introns, while
CD25 and mCD25 was comprised of eight exons and seven
introns (Fig. 1B).
3.2. Prokaryotic expression of chCD25 protein and its
polyclonal and monoclonal antibodies
The pET32a-chCD25 plasmid was transformed into E. coli
BL21 (DE3) strain, and then chCD25 with Trx and His tags
was optimally expressed in E. coli as insoluble inclusions after
induced by a ﬁnal concentration of 1 mM IPTG. The molecu-
lar weight of rchCD25 was approximately 38 kDa (data not
shown). Finally, the puriﬁed rchCD25 protein was acquired
by using a nickel column under denaturing conditions. The
yield of the eluted soluble protein was about 4 mg/L bacterial
culture, as assessed by the Brandford method.
Rabbits and BALB/c mice were immunized with the puriﬁed
rchCD25 protein. Seven hybridoma cell lines secreting anti-
chCD25 antibodies were established and rabbit anti-chCD25
serum was produced. Western blot assays demonstrated that
rabbit anti-chCD25 serum and all seven anti-chCD25 mAbs
had strong binding with the recombinant chCD25 protein,
but none of these antibodies showed any reaction against
Trx or cell lysates of E. coli (data not shown). Furthermore,
the six mAbs belong to IgG1subtype, whereas one mAb be-
longs to IgG2b subtype. All of the light chains of anti-chCD25
mAbs belong to j chain.
3.3. Eukaryotic expression and subcellular distribution of
chCD25 protein
To express chCD25 in eukaryotic cells, the chCD25 cDNA
sequence was cloned into the plasmid pEGFP-C2. At 5 h
post-transfection, the EGFP-chCD25 protein began to pres-
ent on the surface of vero cells. Subsequently, the EGFP-
chCD25 protein could be found in the cytoplasm and nucleus
at 19–24 h post-transfection. The EGFP-chCD25 protein
could be recognized speciﬁcally with seven mAbs and pAb
in immunochemical analysis (data not shown), showing that
the binding epitopes of naturally expressing chCD25 protein
is recognized by mAbs and pAb to chCD25 expressed in
E. coli.
To further localize chCD25 on SMC, the con A-activated
SMC were stained with anti-chCD25 mAbs and pAb in immu-
noﬂuorescence analysis. Only strong bindings of two anti-
chCD25 mAbs and pAb were revealed on the con A-activated
SMC, and the immunoﬂuorescence was mainly presented on
the con A-activated SMC surface (Fig. 2).Fig. 2. Reactivity of the mAbs to chCD25 with eukaryotic chCD25
protein. (A)–(C) reveals that the anti-chCD25 pAb and mAbs (5E1
and 6C9) bind naturally expressed chCD25 molecules on the cell
surface of con A-activated SMC by immunoﬂuorescence staining.3.4. Antibodies to chCD25 inhibit chIL-2-stimulated spleen cell
proliferation
In order to investigate the biological activity of chCD25, the
inhibition of chIL-2-inducing T-cell proliferation was per-
formed. Data shown in Fig. 3 indicate that chIL-2 protein
did not induce in vitro T-cell proliferation after rabbit anti-
chCD25 antibody was mixed with SMC. Among the seven
anti-chCD25 mAbs, only one mAb revealed the inhibiting
activity of chIL-2-inducing T cell proliferation. In addition,
the inhibition of SMC proliferation was dose-dependent. The
evidence demonstrates that the anti-chCD25 pAb and mAb
6C9 block functional epitopes of natural chCD25 directly
binding to chIL-2 protein. But the anit-chCD25 pAb shows
a stronger inhibiting activity than the anti-chCD25 mAb under
the same concentration.
3.5. CD25 expression in chicken tissues
ChCD25 protein expression was assessed by FCM with
mAb 6C9 in normal tissues. In general, chCD25-labelled cells
was a very low level in the lungs, heart, brain, spinal cord, thy-
mus, duodenum, spleen, kidneys, bone marrow of shankbone
antrum, caecal tonsils and bursa of Fabricius (Fig. 4). Spe-
cially the chCD25-labelled cells were next to zero in the bursa
of Fabricius and caecal tonsils. In addition, the frequency of
the double-labelled cells with chicken CD25 and CD41/CD61
was 1.83 ± 0.05% in thrombocytes (Fig. 5).
3.6. Frequency of CD25 expression in chicken SMC population
To analyze the immunophenotype of chCD25+ cells, we de-
tected chCD25 protein in con A-activated chicken splenic
CD4+ or CD8+ or monocyte/macrophage or cd T cell popula-
tion using FCM analysis. Data shown in Fig. 5 illustrate that
the percentage of chCD25-immunophenotype cells was
remarkably increased after SMC and adherent SMC were acti-
vated by con A. In contrast, a lower percentage of chCD25-
immunophenotype cells was revealed in the unstimulated
SMC and adherent SMC. Average frequency of chCD25-la-
beled cells was 24.3 ± 1.84% in the CD8+ population and
6.75 ± 0.49% in the monocyte/macrophage population,0
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Fig. 3. Inhibition of chIL-2-stimulated SMC proliferation. After serial
dilutions, anti-chCD25 mAbs and pAb were incubated with con A-
stimulated SMC followed by chIL-2 protein. chIL-2 and 1640 medium
were used as positive and negative controls. Cell proliferation was
measured as described in Section 2. Values are expressed as the
means ± S.D.
Fig. 4. FCM analysis of chCD25 protein expression in chicken tissues.
The single cell suspensions were prepared respectively from the spleen,
bursa of Fabricius, kidneys, brain, bone marrow of shankbone, cardiac
muscle, duodenum, lungs, spinal cord, thymus and caecal tonsils. Cells
were incubated with mAb 5E1 and a secondary FITC-labeled goat
anti-mouse IgG. Cells incubated with normal mouse serum were used
as negative control.
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Fig. 5. Immunophenotypic cells carrying with chCD25 molecules.
(A)–(D) show respectively the percentage of chCD25+ cells in the
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chCD25 molecules were detected on the surface of cd T cell
population with con A-activated SMC. These data imply that
the chCD25 protein may be expressed by other immunopheno-
typic cells.
3.7. Kinetics of CD25-phenotype cells of chicken infected with
H9N2 avian inﬂuenza virus
To understand the proﬁle of chCD25 expression in vivo,
chCD25-labeled SMC of the H9N2 virus infected chickens
were analyzed using two-color immunoﬂuorescence FCM. As
shown in Fig. 6, when compared with that of the uninfected
chickens, the quantity of chCD25+ SMC, chicken
CD4+CD25+ (ch CD4+CD25+) SMC and chicken
CD8+CD25+ (chCD8+CD25+) SMC decreased slightly in the
inoculated chicken 1 day post-inoculation (p.i). Two days
p.i., numbers of SMC expressing chCD25 and chCD4CD25
and chCD8CD25 molecules appeared to increase remark-
ably and reach a peak. The expression of chCD25,
chCD4CD25, and chCD8CD25 molecules then began to de-
crease gradually by three days p.i., and returned to physiolog-
ical levels by 7 days p.i. Correspondingly, chicken CD4
expression upregulated slightly, whereas chicken CD8 expres-
sion remained unchanged. These data indicate that the balance
of chicken Treg cell proportion change during H9N2 virus
infection.thrombocytes, CD8+ cells, CD4+ cells and monocytes/macrophages.4. Discussion
Human CD25 and mouse CD25 genes have been assigned to
human chromosome 10 and mouse chromosome 2 [40,41],
respectively, and porcine CD25 has been localized to porcine
chromosome 10q6-qter connecting to Vimentin gene [42].
Therefore, it is reasonable to postulate that localization of
CD25 gene on chromosome is species speciﬁc. Indeed, the
chicken CD25 cDNA sequence described in this study was
mapped subsequently onto chicken chromosome 1 by compar-
ing the published chicken genome sequence.
Using rchCD25 protein expressed in E. coli, we produced
pAb and mAbs to chCD25. These pAb and mAbs recognized
CD25 molecules expressed naturally on the surface of SMC(Fig. 2), conﬁrming that anti-chCD25 pAb and mAbs are
capable of binding epitopes on naturally expressed chCD25
molecules. Correspondingly, these pAb and mAbs could inhi-
bit in vitro SMC proliferation induced by chIL-2 protein
(Fig. 3). These data suggest that there is a protein domain of
rchCD25 molecule involved in binding chIL-2. Previous re-
ports considered that CD25 may bind to the amino acids
Lys35, Arg38, Phe42 and Lys43 within IL-2 polypeptide [43],
whereas mouse IL-2 amino acid residues Asn47, Met53,
Phe58, Asp75, Glu76, Val83,129 were critical contact sites for
binding to mouse CD25 [44]. Recent crystallography studies
further conﬁrm that there are two prominent hydrophobic
ridges around residues Phe42 and Tyr45 of IL-2 insert into
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between IL-2 and CD25 in the quaternary complex is com-
posed of helices A and B and part of the AB loop in IL-2
and strands G, C, and D in the D1 domain and strand A in
the D2 domain in CD25 [7]. In the present study, eleven con-
served amino acid residues within an N-terminal exist in
chCD25 when human and mouse CD25 are compared
(Fig. 1). Thus, it is reasonable to postulate that these amino
acid residues are crucial for maintaining the biological func-
tions of chCD25. Indeed, how chCD25 contacts chIL-2 is un-
clear in the quaternary complex. Consequently, the analyses of
crystal structure and functional binding sites of chCD25 are
needed to explain mechanisms governing binding of chCD25
and chIL-2. Although Kolodsick et al [45] have considered
that amino acid residue Asp17 of chIL-2 may be a critical N-
terminal contact site for binding to the chIL-2 R using muta-
tion analysis.
In the early 1980s, some studies suggested that con A, PMA
and ionomycin could upregulate CD25 expression in vitro
[46,47]. However, the study of Treg cells was neglected based
on limitations of the isolation and phenotypic and functional
characterization in the past. Within the last few years, Treg cells
have re-entered the stage of immunology, including naturally
occurring Treg cells and induced Treg cells [14,48]. Recently,
peripheral CD8+CD25+ T lymphocytes were attained from
MHC Class II-deﬁcient mice [24]. Unfortunately, no physio-
logically generated subset of regulatory CD8+ T cells has yet
been characterized in the periphery of mammals. In this study,
FCM analysis showed that chCD25 expression was very low in
the normal tissue cells and the unstimulated SMC, whereas the
upregulation of chCD25 expression was obvious on the cell
surface of con A-activated SMC and those of chickens infected
with the H9N2 virus. Interestingly, although the proportion of
CD4+ and CD8+ immunophenotypic cells with CD25 mole-
cules have shown a remarkable upregulation in our experiment
(Fig. 6), we found that only a portion of monocytes/macro-
phages, thrombocytes, chCD4+ and chCD8+ cells expresschCD25 molecules in vitro and in vivo. Thereby it was reason-
able to hypothesize that many chCD25 molecules were ex-
pressed on the surface of unknown immunophenotypic cells,
and chCD25 expression could be regulated by mitogens and
pathogens.
CD8+CD25+ thymocytes share phenotypic and functional
features with CD4+CD25+ regulatory thymocytes [49]. Several
reports have shown that a potential role of Treg cells
(CD4+CD25+) is suppression of virus-speciﬁc CD8+ T cell re-
sponses during acute and chronic viral infections [50,51]. As
for Treg cells, the information on the role of T
reg cells in the
control of immune responses against infections is still limited.
After chickens were exposed to viral infection, it was unclear
how chicken immune systems regulate its precise immunoreg-
ulatory responses according to current knowledge. In the
present study, during H9N2 virus infection, the amount of
chCD8+ and chCD4+ cells did not revealed signiﬁcant in-
crease. However, SMC expressing chCD25, chCD4CD25,
and chCD8CD25 dramatically increased 2 days p.i., and
reached a peak. Subsequently, the amount of chCD25+,
chCD4+CD25+, and chCD8+CD25+ cells began to decrease
gradually 72 h p.i. (Fig. 6). These data veriﬁed that
chCD4+CD25 and chCD8+CD25 cells were transformed
into chCD4+CD25+ and chCD8+CD25+ cells during H9N2
virus infection. However, we cannot explain the upregulated
roles of chCD25+, chCD4+CD25+, chCD8+CD25+ cells during
viral infection. Therefore further studies of chCD25+ cells are
needed in future.
In conclusion, our results conﬁrmed that our cloned cDNA
was the nucleotide sequence of the chIL-2 receptor, and anti-
chCD25 pAb and mAbs maintained the binding capacity of
the epitopes of nature chCD25. The phenotypic analysis of
chCD25+ cells may help to better identify their exact function.
Further understanding of the kinetics of Treg cells against
avian inﬂuenza virus may provide information about the
mechanisms of protection and a better strategy for disease
control.
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